adult and pediatric
(CRCs) are participating in a
new study that looks at the
safety and efficacy of
pathogen-reduced blood
components. The school
became one of the first two
in the country to enroll a
patient in the Mirasol Plate-
lets in Plasma (MIPLATE)
clinical trial.
ness of Mirasol-treated
apheresis platelets in plasma
versus standard apheresis
platelets in plasma, in sup-
port of a premarket approval
application for the Mirasol
Pathogen Reduction Tech-
nology System. The three-
and-a-half-year, multi-center,
controlled, randomized study
involves patients who have
hypoproliferative thrombo-
cytopenia--a condition char-
count in individuals with
compromised bone marrow
due to hematologic malignan-
cies or treatments such as
chemotherapy.
New Brunswick, at
Rutgers Biomed-
ical and Health
Sciences, is the
principal investiga-
ogy/oncology and a resident
member of Rutgers Cancer
Institute of New Jersey, is the
principal investigator for the
pediatrics study.
to Enroll Patients in Blood Safety Study
and James W. Mackenzie
MD Endowed Chair in
Surgery, has been selected as
the senior associate dean for
clinical affairs for Robert
Wood Johnson Medical
School. Dr. Lee will also
serve as vice president of
clinical affairs of Rutgers
Health Group (RHG). Dr.
Lee will oversee all opera-
tions of the school's clinical
practice in coordination with
Rutgers Health.
sion of cardiothoracic sur-
gery, a position he has con-
tinued to maintain after his
appointment as interim chair
three years ago. During his
ume has grown nearly 50
percent, with significant
improvements in quality met-
rics, including decreases in
mortality rates,
strokes, renal fail-
ure, length of stay,
and readmission
rates. In addition,
the most recent
Society of Thoracic
Surgeons data
revealed that the
cardiothoracic sur-
gery program has achieved a
three-star rating (the highest-
quality measure awarded by
the society) in all areas
reported--aortic valve
replacement (AVR), coronary
artery bypass grafting
(CABG), and AVR/CABG, a
distinction held by no other
ized and a new cohesiveness
and transparency throughout
department overall
have yielded a true
sense of team-driven
health care, with
improved financial
success each year and
increased productivity,
expanded clinical
services, minimal
tional care.
education, and clinical
responsibilities, with nearly
200 published articles and
abstracts, an RO1 and AHA
grant currently in prepara-
continued high reviews as a
mentor and educator.
at St. Vincent's Hospital in
New York, where he served
as chief resident. He per-
formed a research fellowship
at NewYorkPresbyterian
Hospital/Weill Cornell
Medical Center that focused
on gene therapy research for
the treatment of cardiovascu-
lar diseases, culminating in a
National Heart, Lung, and
Blood Institutesponsored
human trial. His clinical car-
diothoracic fellowship was
at NewYorkPresbyterian
Hospital/Weill Cornell
Medical Center and at
Memorial Sloan Kettering
Cancer Center.
O
E
M
R
S
O
O
E
M
R
S
O
C
R
O
N
O